302 related articles for article (PubMed ID: 24536047)
1. HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells.
Lal S; Burkhart RA; Beeharry N; Bhattacharjee V; Londin ER; Cozzitorto JA; Romeo C; Jimbo M; Norris ZA; Yeo CJ; Sawicki JA; Winter JM; Rigoutsos I; Yen TJ; Brody JR
Cancer Res; 2014 Feb; 74(4):1128-40. PubMed ID: 24536047
[TBL] [Abstract][Full Text] [Related]
2. HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells.
Romeo C; Weber MC; Zarei M; DeCicco D; Chand SN; Lobo AD; Winter JM; Sawicki JA; Sachs JN; Meisner-Kober N; Yeo CJ; Vadigepalli R; Tykocinski ML; Brody JR
Mol Cancer Res; 2016 Jul; 14(7):599-611. PubMed ID: 27053682
[TBL] [Abstract][Full Text] [Related]
3. HuR's post-transcriptional regulation of Death Receptor 5 in pancreatic cancer cells.
Pineda DM; Rittenhouse DW; Valley CC; Cozzitorto JA; Burkhart RA; Leiby B; Winter JM; Weber MC; Londin ER; Rigoutsos I; Yeo CJ; Gorospe M; Witkiewicz AK; Sachs JN; Brody JR
Cancer Biol Ther; 2012 Aug; 13(10):946-55. PubMed ID: 22785201
[TBL] [Abstract][Full Text] [Related]
4. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.
Costantino CL; Witkiewicz AK; Kuwano Y; Cozzitorto JA; Kennedy EP; Dasgupta A; Keen JC; Yeo CJ; Gorospe M; Brody JR
Cancer Res; 2009 Jun; 69(11):4567-72. PubMed ID: 19487279
[TBL] [Abstract][Full Text] [Related]
5. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells.
Blanco FF; Jimbo M; Wulfkuhle J; Gallagher I; Deng J; Enyenihi L; Meisner-Kober N; Londin E; Rigoutsos I; Sawicki JA; Risbud MV; Witkiewicz AK; McCue PA; Jiang W; Rui H; Yeo CJ; Petricoin E; Winter JM; Brody JR
Oncogene; 2016 May; 35(19):2529-41. PubMed ID: 26387536
[TBL] [Abstract][Full Text] [Related]
6. Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells.
Jimbo M; Blanco FF; Huang YH; Telonis AG; Screnci BA; Cosma GL; Alexeev V; Gonye GE; Yeo CJ; Sawicki JA; Winter JM; Brody JR
Oncotarget; 2015 Sep; 6(29):27312-31. PubMed ID: 26314962
[TBL] [Abstract][Full Text] [Related]
7. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.
McAllister F; Pineda DM; Jimbo M; Lal S; Burkhart RA; Moughan J; Winter KA; Abdelmohsen K; Gorospe M; Acosta Ade J; Lankapalli RH; Winter JM; Yeo CJ; Witkiewicz AK; Iacobuzio-Donahue CA; Laheru D; Brody JR
Cancer Biol Ther; 2014 Jun; 15(6):688-98. PubMed ID: 24618665
[TBL] [Abstract][Full Text] [Related]
8. Cytokinetic effects of Wee1 disruption in pancreatic cancer.
Chang Q; Chandrashekhar M; Ketela T; Fedyshyn Y; Moffat J; Hedley D
Cell Cycle; 2016; 15(4):593-604. PubMed ID: 26890070
[TBL] [Abstract][Full Text] [Related]
9. Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy.
Huang YH; Peng W; Furuuchi N; DuHadaway JB; Jimbo M; Pirritano A; Dunton CJ; Daum GS; Leiby BE; Brody JR; Sawicki JA
Oncotarget; 2016 Apr; 7(16):21812-24. PubMed ID: 26943573
[TBL] [Abstract][Full Text] [Related]
10. WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner.
Lal S; Zarei M; Chand SN; Dylgjeri E; Mambelli-Lisboa NC; Pishvaian MJ; Yeo CJ; Winter JM; Brody JR
Sci Rep; 2016 Sep; 6():33323. PubMed ID: 27616351
[TBL] [Abstract][Full Text] [Related]
11. Wee1 kinase as a target for cancer therapy.
Do K; Doroshow JH; Kummar S
Cell Cycle; 2013 Oct; 12(19):3159-64. PubMed ID: 24013427
[TBL] [Abstract][Full Text] [Related]
12. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe.
De Witt Hamer PC; Mir SE; Noske D; Van Noorden CJ; Würdinger T
Clin Cancer Res; 2011 Jul; 17(13):4200-7. PubMed ID: 21562035
[TBL] [Abstract][Full Text] [Related]
13. Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy.
Clausse V; Goloudina AR; Uyanik B; Kochetkova EY; Richaud S; Fedorova OA; Hammann A; Bardou M; Barlev NA; Garrido C; Demidov ON
Cell Death Dis; 2016 Apr; 7(4):e2195. PubMed ID: 27077811
[TBL] [Abstract][Full Text] [Related]
14. Posttranscriptional Regulation of
Chand SN; Zarei M; Schiewer MJ; Kamath AR; Romeo C; Lal S; Cozzitorto JA; Nevler A; Scolaro L; Londin E; Jiang W; Meisner-Kober N; Pishvaian MJ; Knudsen KE; Yeo CJ; Pascal JM; Winter JM; Brody JR
Cancer Res; 2017 Sep; 77(18):5011-5025. PubMed ID: 28687616
[TBL] [Abstract][Full Text] [Related]
15. HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.
Jakstaite A; Maziukiene A; Silkuniene G; Kmieliute K; Gulbinas A; Dambrauskas Z
World J Gastroenterol; 2015 Dec; 21(46):13004-19. PubMed ID: 26675757
[TBL] [Abstract][Full Text] [Related]
16. HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer.
Burkhart RA; Pineda DM; Chand SN; Romeo C; Londin ER; Karoly ED; Cozzitorto JA; Rigoutsos I; Yeo CJ; Brody JR; Winter JM
RNA Biol; 2013 Aug; 10(8):1312-23. PubMed ID: 23807417
[TBL] [Abstract][Full Text] [Related]
17. WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry.
Elbæk CR; Petrosius V; Sørensen CS
Mutat Res; 2020; 819-820():111694. PubMed ID: 32120135
[TBL] [Abstract][Full Text] [Related]
18. Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair.
Kausar T; Schreiber JS; Karnak D; Parsels LA; Parsels JD; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA
Neoplasia; 2015 Oct; 17(10):757-66. PubMed ID: 26585231
[TBL] [Abstract][Full Text] [Related]
19. pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs.
Williams TK; Costantino CL; Bildzukewicz NA; Richards NG; Rittenhouse DW; Einstein L; Cozzitorto JA; Keen JC; Dasgupta A; Gorospe M; Gonye GE; Yeo CJ; Witkiewicz AK; Brody JR
PLoS One; 2010 Nov; 5(11):e15455. PubMed ID: 21152064
[TBL] [Abstract][Full Text] [Related]
20. PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.
Jhuraney A; Woods NT; Wright G; Rix L; Kinose F; Kroeger JL; Remily-Wood E; Cress WD; Koomen JM; Brantley SG; Gray JE; Haura EB; Rix U; Monteiro AN
Mol Cancer Ther; 2016 Jul; 15(7):1669-81. PubMed ID: 27196765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
